Allogene Therapeutics
Karen Garry possesses significant experience in accounts payable and financial management, currently serving as the Sr. Accounts Payable Manager at Allogene Therapeutics since September 2019. In this role, Karen oversees a team of six, managing comprehensive processes related to invoice processing, vendor communications, payment approvals, and audit assistance. Prior experience includes positions at Nevro, where Karen was an Accounts Payable Manager and previously managed customer service and order management, and at Acclarent, where responsibilities included accounts receivable and payroll functions. Throughout these positions, Karen demonstrated strong leadership, efficiency in task assignments, and implementation of financial software systems.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.